Samsung Takes the Wheel at a Top Peptide Maker. Now What?
PolyPeptide shareholders just handed Samsung Biologics the board, with 87.9% of shares tendered. What changes for the peptide supply chain, and when.
Summary. PolyPeptide Group, the Swiss contract developer and manufacturer of peptide-based active pharmaceutical ingredients, said on 26 October 2026 that its shareholders approved every board proposal at an extraordinary general meeting in Baar, electing five nominees put forward by Samsung Biologics, including a new chair. The elections take effect only when the public tender offer by Samsung Peptide AG, a wholly owned Samsung Biologics subsidiary, settles.
Research context (RUO). Shareholders also voted to remove the share transfer restrictions and voting limitations from PolyPeptide's articles of association, again conditional on the offer conditions in the 31 August 2026 offer prospectus. According to PolyPeptide's 16 October release, Samsung Peptide and parties acting in concert held 29,123,892 shares, or 87.92% of the issued share capital and voting rights, at the end of the main offer period on 12 October, and declared the offer successful subject to remaining conditions, including regulatory approvals in certain jurisdictions. An additional acceptance period runs from 19 October to 30 October 2026, 4:00 p.m. Swiss time. The deal would put one of the largest independent peptide API contract makers inside a large biologics manufacturing group. For the research supply chain, the practical questions are about continuity: which sites, synthesis and purification processes and quality systems stay in place after a change of control. Those are documented lot by lot. A lot-level certificate of analysis records identity, purity and impurity profile for one batch, with the lot number, test methods, laboratory and date, whoever owns the plant.
This summary is for research-community awareness only and is not legal advice. For research use only. Not for human or veterinary use.